SCHEMBL5756928

SCHEMBL5756928

Cc1ccc(C(=O)NCCc2ccc(C(C)(C)C)cc2)c(=O)n1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.64
ESRRG P62508 11/20 0.54
ESRRB O95718 4/20 0.52
PDE4A P27815 1/20 0.46
PDE4B Q07343 1/20 0.46
PDE4C Q08493 1/20 0.46
PDE4D Q08499 1/20 0.46
DGAT2 Q96PD7 1/20 0.46
CNR2 P34972 2/20 0.45
CNR1 P21554 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
NOTUM Q6P988 1/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
KMT2A Q03164 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALDH1A1 P00352 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5757548 0.92 ELANE (0.66) ELANEESRRGPDE4APDE4BPDE4C
SCHEMBL6217145 0.92 ELANE (0.55) ELANEESRRGESRRBPDE4APDE4B
SCHEMBL27624402 0.91 ELANE (0.65) ELANEESRRGESRRBPDE4APDE4B
SCHEMBL5757915 0.91 ELANE (0.65) ELANEESRRGPDE4APDE4BPDE4C
SCHEMBL5757245 0.91 ELANE (0.65) ELANEPDE4APDE4BPDE4CPDE4D
SCHEMBL5760251 0.90 ELANE (0.64) ELANECNR2CNR1NPC1RAB9A
SCHEMBL5754799 0.90 ELANE (0.64) ELANEESRRGPDE4APDE4BPDE4C
SCHEMBL5755230 0.89 ELANE (0.62) ELANEESRRGPDE4APDE4BPDE4C
SCHEMBL5758364 0.89 ELANE (0.62) ELANEMEN1LMNAKMT2AKDM4E
SCHEMBL5759522 0.89 ELANE (0.61) ELANEPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed
CN-1711243-A 2-pyridone derivatives as inhibitors of neutrophil elastase ASTRAZENECA AB (SE) 2005-12-21 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 ELANE 2/4885ESRRG 2344/4885ESRRB 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.